Back

From identification of high CV risk patients to treatment with PCSK9i: learnings from ODYSSEY OUTCOMES.

28 August 2018 (10:15 - 10:25)
Organised by:
Congress Presentation Part of: From ODYSSEY OUTCOMES results to clinical practice - Identifying patients who may benefit most from PCSK9 inhibition Lipids ESC Premium Access ESC Congress 2018

About the speaker

Photo
Professor Andreas Michael Zeiher

Institute of Cardiovascular Regeneration, Frankfurt (Germany)

2 More presentations in this session

Presentation thumbnail
A deeper dive into key ODYSSEY OUTCOMES results and their impact on patient management.
Professor G. Schwartz (Aurora, US)
Presentation thumbnail
Interaction with the audience
Professor A. Zeiher (Frankfurt, DE)

Access the full session

Session thumbnail
From ODYSSEY OUTCOMES results to clinical practice - Identifying patients who may benefit most from PCSK9 inhibition

The Event

Event poster

ESC Congress 2018

28 August 2018 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study
27 August 2021
thumbnail
Congress Presentation
Elevated lipoprotein(a) identifies patients with acute coronary syndrome who derive earlier and greater cardiovascular benefit of alirocumab, particularly for limb events
31 August 2025
thumbnail
Congress Presentation
2 September 2019
thumbnail
Congress Presentation
Treatment of high- and very high-risk patients for the prevention of cardiovascular events in Europe: baseline demographics from the multinational observational SANTORINI study
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources